Table 2 Trial characteristics
Date of approval | Total | ||||
|---|---|---|---|---|---|
2011–2016 | 2017–2022 | ||||
Type of funding | Non-commercial funding | Industry funding | Non-commercial funding | Industry funding | |
9 | 9 | 6 | 6 | 30 | |
Phase | |||||
II | 4 | 8 | 0 | 5 | 17 |
II/III | 1 | 0 | 2 | 0 | 3 |
III | 4 | 1 | 4 | 1 | 10 |
Trial type | |||||
CTIMP | 3 | 9 | 1 | 6 | 19 |
Non-CTIMP | 6 | 0 | 5 | 0 | 11 |
Cancer type | |||||
Breast | 1 | 3 | 2 | 3 | 9 |
Multiple: breast, lung & prostate | 1 | 0 | 0 | 0 | 1 |
Gynaecological | 0 | 1 | 0 | 1 | 2 |
Head and neck | 1 | 0 | 1 | 0 | 2 |
Lung | 0 | 0 | 1 | 0 | 1 |
Penile | 1 | 0 | 0 | 0 | 1 |
Prostate | 1 | 4 | 2 | 1 | 8 |
Urinary system | 4 | 1 | 0 | 1 | 6 |